首页|期刊导航|中国食品药品监管|论药品上市许可成为民事执行标的的可行性

论药品上市许可成为民事执行标的的可行性OA

Feasibility of Subjecting Drug Marketing Authorizations to Civil Enforcement

中文摘要英文摘要

近年来,司法实践中逐渐出现法院尝试拍卖被执行人持有的药品上市许可以清偿债务的情形,药品上市许可能否成为民事执行标的的问题由此凸显.在药品上市许可持有人(MAH)制度实施前,依据行政许可的一般原理和《中华人民共和国行政许可法》的规定,药品上市许可不可转让,也不能成为民事执行标的.MAH 制度实施后,药品上市许可虽在符合法定条件的前提下可以转让,但转让需经过审批,且转让许可的前置条件涉及对高度复杂技术问题的专业审查,法院缺乏相应的替代审查能力;即便完成 MAH 主体变更,受让人也难以获得包括全部生产工艺在内的完整技术资料,难以实际开展生产并产生相应的经济价值;即使通过拍卖强制执行后,若被执行人或原受托生产企业不予配合,受让人也无法完成生产场地变更并进行生产.因此,药品上市许可成为民事执行标的仍面临较大的法律和现实障碍,有待通过精细化的制度设计予以突破.

In recent years,Chinese courts have increasingly attempted to auction drug marketing authorizations held by judgment debtors to satisfy outstanding debts.This trend has raised an important legal question:whether a drug marketing authorization may be subject to civil enforcement.Prior to the implementation of the marketing authorization holder(MAH)system,a drug marketing authorization,under the general principles of administrative licensing and the Administrative Licensing Law of the People's Republic of China,could neither be transferred nor used as the subject of civil enforcement.Following the introduction of the MAH system,while a drug marketing authorization may be transferred upon satisfaction of statutory conditions and procedures,such a transfer remains subject to regulatory approval.Critically,the preconditions for such a transfer involve regulatory review of highly complex technical matters—an area in which courts lack the capacity to perform substitute review.Moreover,even if a change of MAH is formally approved,the transferee may not necessarily obtain all of the essential technical information and production resources,including the complete manufacturing process documentation.As a result,the transferee may be unable to manufacture the drug or realize the anticipated economic value.Furthermore,following a compulsory auction,if the judgment debtor or the original contract manufacturer refuses to cooperate,the transferee may still be unable to complete the change of manufacturing site and start production.Consequently,significant legal and practical obstacles persist with regard to treating drug marketing authorizations as subjects of civil enforcement.Overcoming these obstacles will require the development of a more refined and tailored institutional framework.

杨翼飞

北京市合达律师事务所

社会科学

药品上市许可民事执行标的药品上市许可持有人制度技术审查

drug marketing authorizationsubject of civil enforcementmarketing authorization holder systemtechnical review

《中国食品药品监管》 2026 (8)

82-91,10

10.3969/j.issn.1673-5390.2026.08.009

评论